Abstract
The penetration of telavancin was 2% into inflamed meninges and ca. 1 per thousand into noninflamed meninges after two intravenous injections (30 mg/kg of body weight). In experimental meningitis, telavancin was significantly superior to vancomycin combined with ceftriaxone against a penicillin-resistant pneumococcal strain. Against a methicillin-sensitive staphylococcal strain, telavancin was slightly but not significantly superior to vancomycin.
MeSH terms
-
Aminoglycosides / pharmacokinetics
-
Aminoglycosides / therapeutic use*
-
Animals
-
Anti-Bacterial Agents / therapeutic use*
-
Disease Models, Animal
-
Lipoglycopeptides
-
Meningitis, Bacterial / drug therapy*
-
Meningitis, Pneumococcal / drug therapy*
-
Microbial Sensitivity Tests
-
Penicillin Resistance*
-
Rabbits
-
Staphylococcal Infections / drug therapy*
-
Staphylococcus aureus / drug effects
-
Streptococcus pneumoniae / drug effects
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Lipoglycopeptides
-
telavancin